Clin2
NCT07221214Possibly a fitRecruiting

Testing a diabetes drug for drinking and heart health in HIV

HIVAlcoholSmoking CigaretteCardiovascular Disease Prevention

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 89 years
Study type
Interventional

Who can take part

  • You are 18 to 89 years old
  • You have HIV and take your HIV medicines regularly (no missed doses for the last week)
  • Your CD4 count was at least 300 in the last year
  • Your body mass index (BMI) is 23 or higher
  • You have had a drink in the past 3 months and your drinking level is moderate or higher
  • You can get mail at a stable address for the next 6 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07040592Recruiting· Phase 2
Semaglutide for HIV and alcohol use

This study is testing whether semaglutide, a medication already used for diabetes and weight loss, can help people with HIV who also have an alcohol use disorder cut back on drinking. It is for patients treated at the Atlanta VA Healthcare System.

Decatur, Georgia
NCT06691243Recruiting· Phase 2
Testing semaglutide for cocaine use in adults

This study tests if the diabetes drug semaglutide (also used for weight loss) can help reduce cocaine use in adults, including those living with HIV. It's free and lasts about 8 weeks.

Washington D.C., District of Columbia
NCT07325500Recruiting· Phase 2
Low dose GLP-1 for heart health in HIV

This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.

Houston, Texas
NCT06546384Not yet recruiting
Semaglutide for alcohol use and liver health in obesity and fatty liver

This study tests if semaglutide (a GLP-1 RA medicine) can reduce alcohol consumption and improve liver fat and metabolism in people with obesity and fatty liver disease who drink above certain levels.

Bern
NCT07223983Recruiting· Phase 1
Semaglutide for alcohol use disorder after weight loss surgery

This trial tests if a once-weekly diabetes medication (semaglutide) can help people with alcohol use disorder who have had gastric bypass or sleeve gastrectomy in the past 7 years. It may reduce alcohol cravings or drinking.

New Haven, Connecticut
NCT07772960Not yet recruiting· Phase 1
Semaglutide for alcohol use and weight loss

This study tests whether semaglutide, a medication that helps with weight loss, can also reduce alcohol cravings and drinking in people with alcohol use disorder. It may help you drink less and lose weight.

New Haven, Connecticut

Hear when a new HIV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.